Baseline characteristics of patients
| Clinical variables . | bsAb (N = 36) . | CAR-T (N = 26) . | Total (N = 62) . | P value . |
|---|---|---|---|---|
| Median age (range) | 66.5 (63.7-73.2) | 65.5 (63-70) | 66 (63-72) | .40 |
| Sex | .22 | |||
| Female | 18 (50.0%) | 9 (34.6%) | 27 (43.5%) | |
| Male | 18 (50.0%) | 17 (65.4%) | 35 (56.5%) | |
| Ethnicity | .20 | |||
| African American | 7 (19.4%) | 2 (7.7%) | 9 (14.5%) | |
| Caucasian | 29 (80.6%) | 23 (88.5%) | 52 (83.9%) | |
| Others | 0 (0.0%) | 1 (3.8%) | 1 (1.6%) | |
| Immunochemical subtype | ||||
| IgG | 24 (66.7%) | 14 (53.8%) | 38 (61.3%) | |
| IgA | 10 (27.8%) | 4 (15.4%) | 14 (22.6%) | |
| IgD | 0 | 1 (3.8%) | 1 (1.6%) | |
| κ light chain | 2 (5.6%) | 3 (11.5%) | 5 (8%) | |
| Λ light chain | 0 | 4 (15.4%) | 4 (8%) | |
| Median prior lines of therapy (range) | 6 (5-7) | 3.5 (2-6) | 5 (4-6) | <.001 |
| Triple class refractory | 36 (100.0%) | 14 (53.8%) | 50 (80.6%) | <.001 |
| ISS stage | .844 | |||
| I | 6 (28.6%) | 4 (23.5%) | 10 (26.3%) | |
| II | 7 (33.3%) | 5 (29.4%) | 12 (31.6%) | |
| III | 8 (38.1%) | 8 (47.1%) | 16 (42.1%) | |
| R-ISS stage | .371 | |||
| I | 3 (37.5%) | 4 (26.7%) | 7 (30.4%) | |
| II | 5 (62.5%) | 7 (46.7%) | 12 (52.2%) | |
| III | 0 (0.0%) | 4 (26.7%) | 4 (17.4%) | |
| CRS grade* | .52 | |||
| 1 | 12 (33.3%) | 6 (23.1%) | 18 (29.0%) | |
| 2 | 2 (5.6%) | 3 (11.5%) | 5 (8.1%) | |
| Median time to therapy from diagnosis, y | 6.6 (0.83-15.5) | 2.6 (0.35-14.4) | 5.2 (0.3-15.5) | .04 |
| Use of tocilizumab | 4 (28.6%) | 5 (55.6%) | 9 (39.1%) | .38 |
| Median follow in months (range), mo | 8.5 (3.5-10.5) | 8.9 (3.1-18.1) | 9 (3.1-18) | .81 |
| Median IgG levels (mg/L) at start of therapy (range) | 889 (333-1931) | 605 (259-1315) | 673 (281-1826) | .13 |
| Baseline hypogammaglobinemia (≤700 mg/dL)† | 20 (80.0%) | 13 (72.2%) | 33 (76.7%) | .551 |
| Baseline severe hypogammaglobinemia (≤400 mg/dL)† | 11 (44.0%) | 8 (44.4%) | 19 (44.2%) | .97 |
| Baseline lymphopenia (≤300/mL) | 8 (23.5%) | 8 (30.8%) | 16 (26.7%) | .53 |
| IVIG supplementation | 8 (22.9%) | 6 (25%) | 14 (23.7%) | .84 |
| Cumulative infections | 25 | 5 | 30 | .01 |
| Number of bacterial infections (n) | 12 | 1 | 13 | .11 |
| Number of viral infections (n) | 8 | 2 | 10 | .69 |
| Aggregated hospitalizations for infection (n) | 15 | 3 | 18 | .03 |
| Average length of stay per patient, mean (SD) | 4.833 (3.460) | 9.000 (5.196) | 5.667 (4.030) | .11 |
| Best response | .75 | |||
| PD | 7 (25.9%) | 6 (30.0%) | 13 (27.7%) | |
| ≥PR | 20 (74.1%) | 14 (70.0%) | 34 (72.3%) |
| Clinical variables . | bsAb (N = 36) . | CAR-T (N = 26) . | Total (N = 62) . | P value . |
|---|---|---|---|---|
| Median age (range) | 66.5 (63.7-73.2) | 65.5 (63-70) | 66 (63-72) | .40 |
| Sex | .22 | |||
| Female | 18 (50.0%) | 9 (34.6%) | 27 (43.5%) | |
| Male | 18 (50.0%) | 17 (65.4%) | 35 (56.5%) | |
| Ethnicity | .20 | |||
| African American | 7 (19.4%) | 2 (7.7%) | 9 (14.5%) | |
| Caucasian | 29 (80.6%) | 23 (88.5%) | 52 (83.9%) | |
| Others | 0 (0.0%) | 1 (3.8%) | 1 (1.6%) | |
| Immunochemical subtype | ||||
| IgG | 24 (66.7%) | 14 (53.8%) | 38 (61.3%) | |
| IgA | 10 (27.8%) | 4 (15.4%) | 14 (22.6%) | |
| IgD | 0 | 1 (3.8%) | 1 (1.6%) | |
| κ light chain | 2 (5.6%) | 3 (11.5%) | 5 (8%) | |
| Λ light chain | 0 | 4 (15.4%) | 4 (8%) | |
| Median prior lines of therapy (range) | 6 (5-7) | 3.5 (2-6) | 5 (4-6) | <.001 |
| Triple class refractory | 36 (100.0%) | 14 (53.8%) | 50 (80.6%) | <.001 |
| ISS stage | .844 | |||
| I | 6 (28.6%) | 4 (23.5%) | 10 (26.3%) | |
| II | 7 (33.3%) | 5 (29.4%) | 12 (31.6%) | |
| III | 8 (38.1%) | 8 (47.1%) | 16 (42.1%) | |
| R-ISS stage | .371 | |||
| I | 3 (37.5%) | 4 (26.7%) | 7 (30.4%) | |
| II | 5 (62.5%) | 7 (46.7%) | 12 (52.2%) | |
| III | 0 (0.0%) | 4 (26.7%) | 4 (17.4%) | |
| CRS grade* | .52 | |||
| 1 | 12 (33.3%) | 6 (23.1%) | 18 (29.0%) | |
| 2 | 2 (5.6%) | 3 (11.5%) | 5 (8.1%) | |
| Median time to therapy from diagnosis, y | 6.6 (0.83-15.5) | 2.6 (0.35-14.4) | 5.2 (0.3-15.5) | .04 |
| Use of tocilizumab | 4 (28.6%) | 5 (55.6%) | 9 (39.1%) | .38 |
| Median follow in months (range), mo | 8.5 (3.5-10.5) | 8.9 (3.1-18.1) | 9 (3.1-18) | .81 |
| Median IgG levels (mg/L) at start of therapy (range) | 889 (333-1931) | 605 (259-1315) | 673 (281-1826) | .13 |
| Baseline hypogammaglobinemia (≤700 mg/dL)† | 20 (80.0%) | 13 (72.2%) | 33 (76.7%) | .551 |
| Baseline severe hypogammaglobinemia (≤400 mg/dL)† | 11 (44.0%) | 8 (44.4%) | 19 (44.2%) | .97 |
| Baseline lymphopenia (≤300/mL) | 8 (23.5%) | 8 (30.8%) | 16 (26.7%) | .53 |
| IVIG supplementation | 8 (22.9%) | 6 (25%) | 14 (23.7%) | .84 |
| Cumulative infections | 25 | 5 | 30 | .01 |
| Number of bacterial infections (n) | 12 | 1 | 13 | .11 |
| Number of viral infections (n) | 8 | 2 | 10 | .69 |
| Aggregated hospitalizations for infection (n) | 15 | 3 | 18 | .03 |
| Average length of stay per patient, mean (SD) | 4.833 (3.460) | 9.000 (5.196) | 5.667 (4.030) | .11 |
| Best response | .75 | |||
| PD | 7 (25.9%) | 6 (30.0%) | 13 (27.7%) | |
| ≥PR | 20 (74.1%) | 14 (70.0%) | 34 (72.3%) |